Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN- 1): A potential mechanism for their antineoplastic properties

International Journal of Tissue Reactions

Volumn 20, Issue 3, 1998, Pages 85-89

  Skopinska Rozewska E ^a   Piazza, G A ^b   Sommer, E ^a   Pamukcu, R ^b   Barcz, E ^a   Filewska, M ^a   Kupis, W ^a   Caban, R ^a   Rudzinski P ^a   Bogdan, J ^a   Mlekodaj, S ^a   Sikorska, E ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^b Cell Pathways Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; SULFONE DERIVATIVE; SULINDAC; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CLINICAL ARTICLE; DRUG MECHANISM; HUMAN; HUMAN CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SULINDAC;

ANIMALIA;

EID: 0032412998     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Thompson H.J., Briggs S., Paranka N.S., et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cane. Inst., 87, 1259, 1995.
2. Rao K.V.N., Detrisac C.J., Steele V.E., Hawk ET., Kelloof E.J., McCormick D.I. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17, 1435, 1996.
3. Castonguay A., Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis, 18, 491, 1997.
4. Thun M., Namboodiri M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593, 1991.
5. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313, 1993.
6. Piazza G.A. , Kulchak-Rahm A.L., Krutzsch M., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55, 3110, 1995.
7. Duggan D.E., Hare LE., Ditzler C.A., Lei B.W., Kwan K.C. The disposition of sulindac. Clin. Pharmacol. Ther., 21, 326, 1997.
8. Duggan D.E., Hooke K.F., Risley E.A., Shen T.Y., VanArman C.G. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Then, 201, 8, 1977.
9. Piazza G.A., Alberts D.S., Hixson LE., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57 (14), 2909, 1997.
10. Cryer B., Feldman M. Effects of nonsteriodal antiinflammatory drugs on endogenous gastrointestional prostaglandins and therapeutic strategies for prevention and treatment of nonsteriodal antiinflammatory drug-induced damage. Arch. Intern. Med., 152, 1145, 1992.
11. Piazza G.A., Rahm A.K., Finn T.S., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57 (12), 2452, 1997.
12. Sidky Y.A., Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J. Exp. Med., 141, 1084, 1975.
13. Skopińska-Rózewska E., Sommer E., et al. Screening of angiogenesis inhibitors by modified tumor-induced angiogenesis (TIA) test in lung cancer. Annales Acad. Med., Bialostociencis, 42 (1), 287, 1997.
14. Auerbach R., Auerbach W., Polakowski I. Assays for angiogenesis: A review. Pharmacol. Therap., 51, 1, 1991.
15. Folkman J. Angiogenesis inhibitors generated by tumors. Molecular Medicine., 1, 120, 1995.
16. Leibovich S.J., Polverini P.J., Fong T.W., Harlow L.A., Koch A.E. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc. Natl. Acad. Sci. USA., 91, 4190, 1994.